BiomX discontinues Phase 2b CF trial of BX004, cuts workforce, explores strategic alternatives

BiomX Inc.

Independent DMC had recommended continuing Study with adjusted dosing, but company cites insufficient resources to execute alternative strategy.
Significant workforce reduction being implemented as part of cost-cutting measures.
BiomX will focus on advancing BX011 for diabetic foot infections, subject to financial resource availability.
Company is reviewing strategic alternatives to maximize shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.